Literature DB >> 29736622

Analysis of clinical characteristics and prognosis factors of 71 cases with HIV-negative Castleman's disease: hypoproteinemia is an unfavorable prognostic factor which should be treated appropriately.

Xuan Lan1, Zhaoming Li1, Mingzhi Zhang2.   

Abstract

PURPOSE: HIV negative Castleman's disease has been reported as a group of poorly understood lymphoproliferative disorder, and we want to explore the clinical feature and prognosis factors of CD.
METHODS: We retrospectively collected the clinical information of 71 CD patients without HIV infection diagnosed in the first affiliated hospital of Zhengzhou university.
RESULTS: Different clinical classifications, including 35 patients (49.30%) with unicentric Castleman disease and 36 (50.7%) with multicentric Castleman disease, has their specific features compared with each other and unfavorable risk factors calculated by the univariate analysis. As for all of CD patients without HIV infection, there were 7 significant risk factors identified by the results of log-rank test, including clinical complaint, edema (hydrothorax, ascites, pelvic effusion), fatigue, anemia, hypoproteinemia and elevated serum β2-MG. Then, we created a Cox regression model of these clinical and statistic significant factors which indicated hypoproteinemia was an independent poor prognosis factors of CD in both univariate and multivariate analysis.
CONCLUSIONS: Our study emphasized the distinction of clinical characteristics between UCD and MCD and the importance of different poor risk factors of different clinical classifications which may directed more precise and appropriate treatment strategy.

Entities:  

Keywords:  Castleman disease; Giant lymph node hyperplasia; HIV; Hypoproteinemia; Prognostic factors

Mesh:

Substances:

Year:  2018        PMID: 29736622     DOI: 10.1007/s00432-018-2647-z

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  36 in total

1.  Serum viral interleukin-6 in AIDS-related multicentric Castleman disease.

Authors:  Y Aoki; G Tosato; T W Fonville; S Pittaluga
Journal:  Blood       Date:  2001-04-15       Impact factor: 22.113

2.  Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra).

Authors:  Hazem El-Osta; Filip Janku; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2010-05-25       Impact factor: 6.261

3.  Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease.

Authors:  Georg Hess; Volker Wagner; Andreas Kreft; Claus Peter Heussel; Christoph Huber
Journal:  Br J Haematol       Date:  2006-09       Impact factor: 6.998

4.  Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease.

Authors:  Thomas S Uldrick; Mark N Polizzotto; Karen Aleman; Kathleen M Wyvill; Vickie Marshall; Denise Whitby; Victoria Wang; Stefania Pittaluga; Deirdre O'Mahony; Seth M Steinberg; Richard F Little; Robert Yarchoan
Journal:  Blood       Date:  2014-10-20       Impact factor: 22.113

5.  High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients.

Authors:  E Oksenhendler; G Carcelain; Y Aoki; E Boulanger; A Maillard; J P Clauvel; F Agbalika
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

6.  Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease.

Authors:  Laurence Gérard; Jean-Marie Michot; Sara Burcheri; Claire Fieschi; Pacale Longuet; Véronique Delcey; Véronique Meignin; Felix Agbalika; Sylvie Chevret; Eric Oksenhendler; Lionel Galicier
Journal:  Blood       Date:  2012-01-05       Impact factor: 22.113

Review 7.  FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease.

Authors:  Albert Deisseroth; Chia-Wen Ko; Lei Nie; Jeanne F Zirkelbach; Liang Zhao; Julie Bullock; Nitin Mehrotra; Pedro Del Valle; Haleh Saber; Christopher Sheth; Brenda Gehrke; Robert Justice; Ann Farrell; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2015-01-19       Impact factor: 12.531

8.  IL-1RA agonist (anakinra) in the treatment of multifocal castleman disease: case report.

Authors:  Caroline Galeotti; Tu-Anh Tran; Stéphanie Franchi-Abella; Monique Fabre; Danièle Pariente; Isabelle Koné-Paut
Journal:  J Pediatr Hematol Oncol       Date:  2008-12       Impact factor: 1.289

9.  Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial.

Authors:  Laurence Gérard; Alice Bérezné; Lionel Galicier; Véronique Meignin; Martine Obadia; Nathalie De Castro; Christine Jacomet; Renaud Verdon; Isabelle Madelaine-Chambrin; Emmanuelle Boulanger; Sylvie Chevret; Felix Agbalika; Eric Oksenhendler
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544

Review 10.  [Pharmacological and clinical profile of anti-human IL-6 receptor antibody (tocilizumab, ACTEMRA), a novel therapeutic drug for Castleman's disease].

Authors:  Yoshiyuki Ohsugi; Nobuyuki Tsuchimoto
Journal:  Nihon Yakurigaku Zasshi       Date:  2005-12
View more
  4 in total

1.  Clinical characteristics and outcomes of Castleman disease: a multicenter Consortium study of 428 patients with 15-year follow-up.

Authors:  Wanying Liu; Qingqing Cai; Tiantian Yu; Paolo Strati; Frederick B Hagemeister; Qiongli Zhai; Mingzhi Zhang; Ling Li; Xiaosheng Fang; Jianyong Li; Ruifang Sun; Shanxiang Zhang; Hanjin Yang; Zhaoming Wang; Wenbian Qian; Noriko Iwaki; Yasuharu Sato; Eric Oksenhendler; Zijun Y Xu-Monette; Ken H Young; Li Yu
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

2.  Comprehensive analysis of 65 patients with Castleman disease in a single center in China.

Authors:  Xi-Qian Wang; Nian-Nian Zhong; Qi Sun; Si-Chen Yan; Guang-Cai Xu; Yong-Gong Wang; Li-Wei Peng; Bing Liu; Lin-Lin Bu
Journal:  Sci Rep       Date:  2022-05-24       Impact factor: 4.996

3.  Clinical and Molecular Characteristics of 60 Patients With Human Immunodeficiency Virus-Negative Castleman Disease.

Authors:  Siyu Qian; Mengjie Ding; Huting Hou; Zeyuan Wang; Jieming Zhang; Yue Zhang; Meng Dong; Linan Zhu; Guannan Wang; Wencai Li; Xudong Zhang
Journal:  Front Immunol       Date:  2022-05-17       Impact factor: 8.786

4.  International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.

Authors:  Frits van Rhee; Eric Oksenhendler; Gordan Srkalovic; Peter Voorhees; Megan Lim; Angela Dispenzieri; Makoto Ide; Sophia Parente; Stephen Schey; Matthew Streetly; Raymond Wong; David Wu; Ivan Maillard; Joshua Brandstadter; Nikhil Munshi; Wilbur Bowne; Kojo S Elenitoba-Johnson; Alexander Fössa; Mary Jo Lechowicz; Shanmuganathan Chandrakasan; Sheila K Pierson; Amy Greenway; Sunita Nasta; Kazuyuki Yoshizaki; Razelle Kurzrock; Thomas S Uldrick; Corey Casper; Amy Chadburn; David C Fajgenbaum
Journal:  Blood Adv       Date:  2020-12-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.